SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals surges on launching Single Inhaler Triple Therapy AIRZ-FF for COPD

11 May 2020 Evaluate
Glenmark Pharmaceuticals is currently trading at Rs. 334.90, up by 1.20 points or 0.36% from its previous closing of Rs. 333.70 on the BSE.

The scrip opened at Rs. 336.30 and has touched a high and low of Rs. 339.50 and Rs. 329.20 respectively. So far 99017 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 626.30 on 10-May-2019 and a 52 week low of Rs. 168.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 347.50 and Rs. 322.90 respectively. The current market cap of the company is Rs. 9432.88 crore.

The promoters holding in the company stood at 46.59%, while Institutions and Non-Institutions held 37.20% and 16.21% respectively.

Glenmark Pharmaceuticals has launched of a Single Inhaler Triple Therapy AIRZ-FF - a combination of two bronchodilators, Glycopyrronium & Formoterol and the inhalation corticosteroid Fluticasone propionate, for Chronic Obstructive Pulmonary Disease (COPD).

This new triple therapy innovation offers significant bronchodilation (making breathing easier), reduces risk of severe attacks, and eliminates dependence on multiple inhalers. The reduction in risk of severe attacks decreases the requirement for hospitalization, a benefit of high significance in current prevailing situation.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2243.80 -4.10 (-0.18%)
20-Apr-2026 11:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.10
Dr. Reddys Lab 1238.25
Cipla 1238.70
Zydus Lifesciences 941.50
Lupin 2327.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×